Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_assertion type Assertion NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_head.
- NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_assertion description "[Lack of CCL2 mRNA expression (15 samples; 16%) was associated with increased cumulative relapse-free survival (log rank test, p = 0.030), increased cumulative overall survival (log rank test, p = 0.024), less post-operative surgery, reduced local and distant recurrence, reduced vascular invasion, and smaller tumour size (<40 mm).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_provenance.
- NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_assertion evidence source_evidence_literature NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_provenance.
- NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_assertion SIO_000772 16435282 NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_provenance.
- NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_assertion wasDerivedFrom befree-20150227 NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_provenance.
- NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_assertion wasGeneratedBy ECO_0000203 NP685074.RAQvQAsnWX_8AUZdrc0qGWX_Uv9PClT4GfYPhlZZ9CwI4130_provenance.